Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) Research & Development (2019 - 2025)

Pulmonx (LUNG) has disclosed Research & Development for 7 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • Quarterly Research & Development rose 29.43% to $4.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $18.9 million through Sep 2025, up 8.27% year-over-year, with the annual reading at $17.6 million for FY2024, 2.82% down from the prior year.
  • Research & Development for Q3 2025 was $4.8 million at Pulmonx, down from $5.3 million in the prior quarter.
  • The five-year high for Research & Development was $5.7 million in Q2 2023, with the low at $2.8 million in Q3 2021.
  • Average Research & Development over 5 years is $4.2 million, with a median of $4.0 million recorded in 2024.
  • The sharpest move saw Research & Development surged 145.86% in 2021, then fell 11.28% in 2024.
  • Over 5 years, Research & Development stood at $3.7 million in 2021, then grew by 5.26% to $3.9 million in 2022, then decreased by 0.18% to $3.9 million in 2023, then grew by 2.7% to $4.0 million in 2024, then grew by 21.12% to $4.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $4.8 million, $5.3 million, and $4.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.